UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Journal of medicinal chemistry, 2005-07, Vol.48 (15), p.5025-5037

2005

Volltextzugriff (PDF)

Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice

Diabetes (New York, N.Y.), 2006-01, Vol.55 (1), p.240-248

2006

Volltextzugriff (PDF)

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1 H -pyrazol-1-yl)methyl)phosphonate (BMS-820132)

Journal of medicinal chemistry, 2022-03, Vol.65 (5), p.4291-4317

2022

Volltextzugriff (PDF)

Optimization of Activity, Selectivity, and Liability Profiles in 5‑Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)‑2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo‑5H‑pyrrolo[3,4‑b]pyridin-6(7H)‑yl)‑N,N‑dimethylacetamide (BMS-767778)

Journal of medicinal chemistry, 2013-09, Vol.56 (18), p.7343-7357

2013

Volltextzugriff (PDF)

POLYAK–VIRO FORMULAS FOR COEFFICIENTS OF THE CONWAY POLYNOMIAL

Journal of knot theory and its ramifications, 2009-06, Vol.18 (6), p.773-783

2009

Volltextzugriff (PDF)

Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists

Bioorganic & medicinal chemistry letters, 2015-03, Vol.25 (6), p.1196-1205

2015

Volltextzugriff (PDF)

7-Oxopyrrolopyridine-derived DPP4 inhibitors—mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site

Bioorganic & medicinal chemistry letters, 2011-11, Vol.21 (22), p.6646-6651

2011

Volltextzugriff (PDF)

Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor α Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453)

Journal of medicinal chemistry, 2010-04, Vol.53 (7), p.2854-2864

2010

Volltextzugriff (PDF)

Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate ( Sa )-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5 H -pyrrolo[3,4- b ]pyridin-6(7 H )-yl)- N , N -dimethylacetamide (BMS-767778)

Journal of medicinal chemistry, 2013-09, Vol.56 (18), p.7343-7357

2013

Volltextzugriff (PDF)

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-l-cis-4,5-methanoprolinenitrile-Based Inhibitors

Journal of medicinal chemistry, 2004-05, Vol.47 (10), p.2587-2598

2004

Volltextzugriff (PDF)

Design, synthesis and structure–activity relationships of azole acids as novel, potent dual PPAR α/γ agonists

Bioorganic & medicinal chemistry letters, 2009-03, Vol.19 (5), p.1451-1456

2009

Volltextzugriff (PDF)

Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists

Bioorganic & medicinal chemistry, 2008-03, Vol.18 (6), p.1939-1944

2008

Volltextzugriff (PDF)

Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor [alpha] Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453)

Journal of medicinal chemistry, 2010-04, Vol.53 ((7) ; 04, 2010)

2010

Volltextzugriff (PDF)

Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists

Bioorganic & medicinal chemistry, 2008-03, Vol.18 (6), p.1939-1944

2008

Volltextzugriff (PDF)

Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters

Arteriosclerosis, thrombosis, and vascular biology, 1995-03, Vol.15 (3), p.349-358

1995

Volltextzugriff (PDF)

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

The New England journal of medicine, 2021-04, Vol.384 (16), p.1491-1502

2021

Volltextzugriff (PDF)

GALTON-WATSON MODELS FOR TOWNSEND DISCHARGE EXPERIMENTS (STOCHASTIC PROCESSES, ELECTRICAL BREAKDOWN)

CAP, DANIEL MICHAEL

1985

Volltextzugriff (PDF)

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-04, Vol.327 (13), p.1247

2022

Volltextzugriff (PDF)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

The New England journal of medicine, 2021-08, Vol.385 (9), p.777-789

2021

Volltextzugriff (PDF)

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

The New England journal of medicine, 2021-08, Vol.385 (9), p.790-802

2021

Volltextzugriff (PDF)

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2020-10, Vol.324 (13), p.1317

2020

Volltextzugriff (PDF)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Intensive care medicine, 2021-08, Vol.47 (8), p.867-886

2021

Volltextzugriff (PDF)

The Etiology of Community-Acquired Pneumonia in Australia: Why Penicillin plus Doxycycline or a Macrolide Is the Most Appropriate Therapy

Clinical infectious diseases, 2008-05, Vol.46 (10), p.1513-1521

2008

Volltextzugriff (PDF)

1 – 25 von 245

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(208)
Mit Volltextzugriff
(195)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(236)
Deutsch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1 H -pyrazol-1-yl)methyl)phosphonate (BMS-820132)

Optimization of Activity, Selectivity, and Liability Profiles in 5‑Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)‑2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo‑5H‑pyrrolo[3,4‑b]pyridin-6(7H)‑yl)‑N,N‑dimethylacetamide (BMS-767778)

POLYAK–VIRO FORMULAS FOR COEFFICIENTS OF THE CONWAY POLYNOMIAL

Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists

Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

7-Oxopyrrolopyridine-derived DPP4 inhibitors—mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site

Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor α Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453)

Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate ( Sa )-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5 H -pyrrolo[3,4- b ]pyridin-6(7 H )-yl)- N , N -dimethylacetamide (BMS-767778)

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-l-cis-4,5-methanoprolinenitrile-Based Inhibitors

Design, synthesis and structure–activity relationships of azole acids as novel, potent dual PPAR α/γ agonists

Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists

Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor [alpha] Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453)

Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists

Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

GALTON-WATSON MODELS FOR TOWNSEND DISCHARGE EXPERIMENTS (STOCHASTIC PROCESSES, ELECTRICAL BREAKDOWN)

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

The Etiology of Community-Acquired Pneumonia in Australia: Why Penicillin plus Doxycycline or a Macrolide Is the Most Appropriate Therapy

Suchergebnisse filtern